Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Maintaining professional activity during breast cancer treatment.

Ganem G, Antoine EC, Touboul C, Naman H, Dohollou N, Facchini T, Coscas Y, Lortholary A, Catala S, Jacquot S, Lhomel C, Eisinger F.

Eur J Cancer Care (Engl). 2016 May;25(3):458-65. doi: 10.1111/ecc.12460. Epub 2016 Feb 18.

PMID:
26891443
2.

Lung cancer risks, beliefs and healthcare access among the underprivileged.

Morère JF, Viguier J, Touboul C, Pivot X, Blay JY, Coscas Y, Lhomel C, Eisinger F.

Eur J Cancer Prev. 2015 Jun;24 Suppl:S82-6. doi: 10.1097/CEJ.0000000000000143.

PMID:
26016793
3.

Social stratification, risk factor prevalence and cancer screening attendance.

Eisinger F, Viguier J, Touboul C, Coscas Y, Pivot X, Blay JY, Lhomel C, Morère JF.

Eur J Cancer Prev. 2015 Jun;24 Suppl:S77-81. doi: 10.1097/CEJ.0000000000000144.

PMID:
26016792
4.

Breast cancer screening controversy: too much or not enough?

Pivot X, Viguier J, Touboul C, Morère JF, Blay JY, Coscas Y, Lhomel C, Eisinger F.

Eur J Cancer Prev. 2015 Jun;24 Suppl:S73-6. doi: 10.1097/CEJ.0000000000000145.

PMID:
26016791
5.

Cancer screening in France: third edition of the EDIFICE survey.

Viguier J, Morère JF, Touboul C, Coscas Y, Blay JY, Lhomel C, Pivot X, Eisinger F.

Eur J Cancer Prev. 2015 Jun;24 Suppl:S68-72. doi: 10.1097/CEJ.0000000000000146.

PMID:
26016790
6.

Prostate cancer screening: contrasting trends.

Eisinger F, Morère JF, Touboul C, Pivot X, Coscas Y, Blay JY, Lhomel C, Viguier J.

Cancer Causes Control. 2015 Jun;26(6):949-52. doi: 10.1007/s10552-015-0573-9. Epub 2015 Mar 31.

PMID:
25822574
7.

Feasibility of radiation therapy in patients 90years of age and older: a French multicentre analysis.

Chargari C, Moriceau G, Auberdiac P, Guy JB, Assouline A, Tinquaut F, Falk AT, Eddekkaoui H, Bourmaud A, Coscas Y, Annede P, Rivoirard R, Mery B, Trone JC, Otmezguine Y, Pacaut C, Bauduceau O, Vedrine L, Merrouche Y, Magne N.

Eur J Cancer. 2014 May;50(8):1490-7. doi: 10.1016/j.ejca.2014.02.012. Epub 2014 Mar 7.

PMID:
24613621
8.

Increasing coverage rates for mammographic screening in France in older women--16 years of follow-up.

Eisinger F, Beck F, Viguier J, Blay JY, Coscas Y, Roussel C, Morère JF, Pivot X.

Breast J. 2011 Nov-Dec;17(6):686-8. doi: 10.1111/j.1524-4741.2011.01169.x. No abstract available.

PMID:
22050283
9.

Added value of molecular targeted agents in oncology.

Soria JC, Blay JY, Spano JP, Pivot X, Coscas Y, Khayat D.

Ann Oncol. 2011 Aug;22(8):1703-16. doi: 10.1093/annonc/mdq675. Epub 2011 Feb 7. Review.

10.

Breast cancer screening in women aged 50-74 years: is there room for improvement?

Morère JF, Pivot X, Viguier J, Blay JY, Calazel-Benque A, Coscas Y, Roussel C, Eisinger F.

Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S8-S12. doi: 10.1097/01.cej.0000391562.18512.4a.

PMID:
21245683
11.

Impact of general practitioners' sex and age on systematic recommendation for cancer screening.

Eisinger F, Pivot X, Coscas Y, Viguier J, Calazel-Benque A, Blay JY, Roussel C, Morère JF.

Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S39-41. doi: 10.1097/01.cej.0000391570.71877.18.

PMID:
21245680
12.

Impact of awareness of cancer among acquaintances on cancer screening attendance.

Eisinger F, Blay JY, Morère JF, Coscas Y, Calazel-Benque A, Roussel C, Pivot X.

Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S36-8. doi: 10.1097/01.cej.0000391569.33759.5b.

PMID:
21245679
13.

Screening for prostate cancer: growth without control.

Eisinger F, Blay JY, Pivot X, Morère JF, Coscas Y, Calazel-Benque A, Roussel C, Viguier J.

Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S33-5. doi: 10.1097/01.cej.0000391568.26136.bc.

PMID:
21245678
14.

Organized colorectal cancer screening programmes: how to optimize efficiency in the general population.

Calazel-Benque A, Viguier J, Roussel C, Pivot X, Eisinger F, Blay JY, Coscas Y, Morère JF.

Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S20-5. doi: 10.1097/01.cej.0000391566.41383.61.

PMID:
21245676
15.

Mammography utilization in women aged 40-49 years: the French EDIFICE survey.

Pivot X, Eisinger F, Blay JY, Coscas Y, Calazel-Benque A, Viguier J, Roussel C, Morère JF.

Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S16-9. doi: 10.1097/01.cej.0000391565.41383.ba.

PMID:
21245674
16.

Uptake of breast cancer screening in women aged over 75 years: a controversy to come?

Eisinger F, Viguier J, Blay JY, Morère JF, Coscas Y, Roussel C, Pivot X.

Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S13-5. doi: 10.1097/01.cej.0000391564.03265.3f.

PMID:
21245673
17.

[Edifice program: analysis of screening exam practices for cancer in France].

Blay JY, Eisinger F, Rixe O, Calazel-Benque A, Morère JF, Cals L, Coscas Y, Dolbeault S, Namer M, Serin D, Roussel C, Pivot X.

Bull Cancer. 2008 Nov;95(11):1067-73. doi: 10.1684/bdc.2008.0747. French.

18.

Breast cancer screening in France: results of the EDIFICE survey.

Pivot X, Rixe O, Morere J, Coscas Y, Cals L, Namer M, Serin D, Dolbeault S, Eisinger F, Roussel C, Blay J.

Int J Med Sci. 2008 May 24;5(3):106-12.

19.

Staged laparoscopic adjuvant intraperitoneal chemohyperthermia after complete resection for locally advanced colorectal or gastric cancer: a preliminary experience.

Chouillard E, Ata T, De Jonghe B, Maggiori L, Helmy N, Coscas Y, Outin H.

Surg Endosc. 2009 Feb;23(2):363-9. doi: 10.1007/s00464-008-9946-4. Epub 2008 May 7.

PMID:
18461388
20.

Impact of organised programs on colorectal cancer screening.

Eisinger F, Cals L, Calazel-Benque A, Blay JY, Coscas Y, Dolbeault S, Namer M, Pivot X, Rixe O, Serin D, Roussel C, Morère JF; EDIFICE committee.

BMC Cancer. 2008 Apr 15;8:104. doi: 10.1186/1471-2407-8-104.

21.

Cancer screening in France: subjects' and physicians' attitudes.

Eisinger F, Blay JY, Morère JF, Rixe O, Calazel-Benque A, Cals L, Coscas Y, Dolbeault S, Namer M, Serin D, Roussel C, Pivot X; EDIFICE Committee.

Cancer Causes Control. 2008 May;19(4):431-4. Epub 2007 Dec 18.

22.

[A rare cause of sub-occlusive syndrome].

Thelier N, Zuech P, Cazaban A, Misbahi R, Coscas Y, Bellamy J, Veyssier-Belot C.

Rev Med Interne. 2006 Feb;27(2):152-3. Epub 2005 Dec 27. French. No abstract available.

PMID:
16406162
23.

Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.

Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM.

J Clin Oncol. 2005 May 20;23(15):3343-51. Epub 2005 Feb 28.

PMID:
15738542
24.
25.

Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study.

Horiot JC, Lipinski F, Schraub S, Maulard-Durdux C, Bensadoun RJ, Ardiet JM, Bolla M, Coscas Y, Baillet F, Coche-Dequéant B, Urbajtel M, Montbarbon X, Bourdin S, Wibault M, Alfonsi M, Calais G, Desprez P, Pene F, Lapeyre M, Vinke J, Maral J.

Radiother Oncol. 2000 Jun;55(3):233-9.

PMID:
11041775
27.
28.
29.

Estrogen and progesterone receptors in cervical human papillomavirus related lesions.

Monsonego J, Magdelenat H, Catalan F, Coscas Y, Zerat L, Sastre X.

Int J Cancer. 1991 Jun 19;48(4):533-9.

PMID:
1646176
30.

Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease.

Andrieu JM, Ifrah N, Payen C, Fermanian J, Coscas Y, Flandrin G.

J Clin Oncol. 1990 Jul;8(7):1148-54. Review.

PMID:
2193118
31.

[Supratentorial glioblastoma in adults. Therapeutic results].

Dana M, Gerodolle M, Koskas Y, Misset JL, Raverdy P, Coscas Y, Miot C, Rougerie J.

Presse Med. 1985 May 25;14(21):1173-6. French.

PMID:
2987901
32.

Extent of radiotherapy for seminomas.

Dana M, Koskas Y, Miot C, Coscas Y, Narès S.

Prog Clin Biol Res. 1985;203:345-50. No abstract available.

PMID:
3832092
33.

[An unusual form of neoplastic lymphangitis in an irradiated field].

Dana M, Coscas Y, Koskas Y, Miot C.

Ann Dermatol Venereol. 1984;111(9):799-802. French.

PMID:
6517447
34.

[Hodgkin's disease: treatment of clinical stages II3+A, IB, IIB, IIIA and IIIB with short chemotherapy (3 MOPP, or 3 CVPP), splenectomy and limited irradiation. Results after 4 years of a prospective protocol including 94 patients].

Andrieu JM, Casassus P, Coscas Y, Darmont J, Goubeau C, Katz M, Jacquillat C, Tricot G, Weil M.

Bull Cancer. 1982;69(4):321-9. French. No abstract available.

PMID:
6897520

Supplemental Content

Loading ...
Support Center